BDCA2-Targeting Antibody May Be Effective for Cutaneous Lupus

(MedPage Today) -- Treatment with an investigational drug targeting the blood dendritic cell antigen 2 (BDCA2) receptor reduced skin disease activity in patients with cutaneous lupus erythematosus, the phase II LILAC study showed.
In patients...

Source: MedPage Today Dermatology - July 28, 2022 Category: Dermatology Source Type: news